dorsolateral prefrontal cortex dlpfc modulation via repetitive transcranial magnetic stimulation rtms to restore brain network function in treatment resistant depression clinical trial intelligence

Quantitative Electroencephalography to Longitudinally Assess the Functional Brain Signature of Treatment-resistant Depression and Recovery With Therapeutic Neuromodulation

This clinical trial, sponsored by Sunnybrook Health Sciences Centre, investigates the efficacy of rTMS combined with dry quantitative EEG (qEEG) technology to personalize treatment for patients with treatment-resistant depression. The market for depression treatments is substantial, with increasing demand for innovative therapies that address unmet needs. The use of qEEG may provide a competitive edge by enabling real-time monitoring of brain activity and treatment response, potentially leading to improved patient outcomes and reduced relapse rates. Given the rising prevalence of depression globally, successful outcomes could position the sponsor favorably within the neuromodulation market, which is projected to grow significantly. Diligence should focus on the scalability of the qEEG technology and the regulatory landscape surrounding neuromodulation devices.

Matched by target_normalized: Dorsolateral prefrontal cortex (DLPFC) modulation via repetitive transcranial magnetic stimulation (rTMS) to restore brain network function in treatment-resistant depression.